Before the arrival of COVID-19, privately held Spokane-based biotechnology company GenPrime Inc. started developing a digital reader and mobile application that could read diagnostic tests more quickly and accurately.
Now, between the pandemic and an explosion of telemedicine use in 2020, company executives said they believe the company is on the verge of unprecedented growth.
“What we’ve developed is a way to make those tests more reliable by getting a digital reading of the results as opposed to a subjective interpretation by eye,” company CEO Buck Somes said.
Somes also said GenPrime is involved in other soon-to-be developed products, which he declines to discuss further.
Company executives also declined to disclose company revenues. However, Richard Van Bibber GenPrime chief technology officer said: “Ten times growth over the next five years is not out of the question.”
Founded in 1997 on the Eastern Washington University campus, the company developed technology that was used in counting live bacteria and yeast-testing technology in the biofuel and brewing industries.
It later developed rapid-detection devices for substances posing a biological threat, and in 2014 launched technologies with the capability to detect drug use.
As for the recently developed digital reader and mobile applications, Somes said the results can be inserted into digital format and entered directly into electronic medical records.
He feels the company is positioned well to introduce technologies that can serve the medical records market.
Tom Douthitt, GenPrime’s chief commercial officer, said the company is banking on the projection that consumer use of telehealth only will grow in the future.
“Sometimes that can be a blip and then a return to normal,” Douthitt said, referring to the public’s concerns about visiting medical offices and hospitals during the height of the pandemic.
“But what we saw is that providers like the idea of having (telemedicine) as a service,” he said, “and users like the idea of being able to call in for their basic health care.”
What that has created for medical test manufacturers –GenPrime’s customer base – is a market for products that need to be designed in a simpler fashion for the general public.
“The importance of accuracy in reading those results has suddenly skyrocketed,” he said. “A lot of internal resources and our growth is going to be zeroed in on addressing those emerging market needs.”
GenPrime frequently collaborates with Spokane-based Gestalt Diagnostics LLC, which develops software for pathologists.
Gestalt CEO Dan Roark serves on GenPrime’s board of directors, Douthitt said.
“They’re digitizing samples for analysis of lab tests while we’re reading samples for lateral assay tests,” Douthitt said. “We’re sharing information and doing work for them as well. We have a great relationship with Dan.”
GenPrime’s digital-reading technology was designed to more accurately capture the results of lateral flow assay tests, or rapid tests that detect target substances in liquid samples, such as pregnancy tests.
The company’s recently developed image-analysis software now can analyze tests more effectively with an image from a mobile device, he said.
“It takes human error out of both those steps. It makes the test much more reliable,” Douthitt said.
GenPrime is ready to make this anticipated leap with the goal of continuing to remain a very lean operation, Somes said.
“We aren’t developing large sales teams because we’re not going direct to customer,” Somes said. “Our customers are the businesses that already build the tests.”
The company makes its home in a first-floor suite at 502 W. Riverside Ave. in downtown Spokane.
GenPrime also occupies basement-level space that accommodates the company’s laboratory facility.
The basement also features a former bank vault that company officials have converted into a…